# EDGAR Filing Document

**Accession Number:** 0001601485
**File Stem:** 0001601485-26-000029
**Filing Date:** 2026-3
**Character Count:** 2324
**Document Hash:** f8747156606863c8102dfc4064918760
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001601485-26-000029.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001601485-26-000029

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elicio Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001601485
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 113430072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 451 D STREET, 5TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (857) 209-0050

**MAIL ADDRESS:**
- **STREET 1:** 451 D STREET, 5TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Angion Biomedica Corp.
- **DATE OF NAME CHANGE:** 20140228

**ELICIO THERAPEUTICS, INC.**

**451 D Street, 5**<sup>th</sup> **Floor**

**Boston, MA 02210**

March 12, 2026

**VIA EDGAR**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Daniel Crawford

Re: **Elicio Therapeutics, Inc.**

**Registration Statement on Form S-3, as amended**

**Filed March 12, 2026**

**File No. 333-293861 (the "Registration Statement")**

**Acceleration Request**

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Elicio Therapeutics, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement to Monday, March 16, 2026, at 9:00 a.m., Eastern Time, or as soon as thereafter practicable.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request.

Very truly yours,

ELICIO THERAPEUTICS, INC.

<u>/s/ Robert Connelly</u> 

Robert Connelly

President and Chief Executive Officer

cc: *<u>Elicio Therapeutics, Inc.</u>*

Megan Filoon

<br>